Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. RYSTIGGO (rozanolixizumab)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

RYSTIGGO (rozanolixizumab)

Medicine - Posted on Mar 06 2025
Active substance (DCI)
  • rozanolixizumab
history (3)
  • 2/26/25

    RYSTIGGO (rozanolixizumab) - Myasthénie

    Primo-inscription L'essentiel Avis favorable au remboursement uniquement en addition au traitement standard, incluant les im...
    CAV :
    54321
    icône flèche
  • 4/24/24

    RYSTIGGO (rozanolixizumab) - Myasthenia

    Summary of opinion Favourable opinion for reimbursement only “as an add-on to standard therapy, including first-line immunos...
    CAV :
    54321
    icône flèche
  • 4/25/24

    RYSTIGGO (rozanolixizumab) - Myasthénie

    Autorisation d’accès précoce refusée à la spécialité RYSTIGGO (rozanolixizumab) dans l'indication « « En association au trai...
    icône flèche
Technical information
ATC code
  • L04AG16
Manufacturer
UCB PHARMA S.A.
Presentation

RYSTIGGO 140 mg/mL, solution injectable par voie sous-cutanée
1 flacon en verre de 2 ml (CIP : 34009 302 847 4 2)

RYSTIGGO 140 mg/mL, solution injectable
1 flacon en verre de 3 mL (CIP : 34009 303 007 6 3)
1 flacon en verre de 4 mL (CIP : 34009 303 007 7 0)

All our publications
    Autoimmune diseases Congenital, genetic and rare diseases Drug therapy Neuromuscular diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
KbmLYYLafdNw0JHQ